Search

Your search keyword '"Nagrial A"' showing total 1,235 results

Search Constraints

Start Over You searched for: Author "Nagrial A" Remove constraint Author: "Nagrial A"
1,235 results on '"Nagrial A"'

Search Results

1. A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia

2. DPYD genotype-guided dose personalisation for fluoropyrimidine-based chemotherapy prescribing in solid organ cancer patients in Australia: GeneScreen 5-FU study protocol

3. A signal-seeking phase 2 study of Trastuzumab emtansine in tumours harbouring HER2 amplification or mutation

4. Real-World outcomes of Non-Small cell lung cancer patients harbouring KRAS G12C and KRAS G12D mutations

5. Nivolumab combination therapies in patients with advanced gastric and gastroesophageal junction cancer: the phase II FRACTION gastric cancer study

7. Radiotherapy Improves Survival in NSCLC After Oligoprogression on Immunotherapy: A Cohort Study

8. Plinabulin plus docetaxel versus docetaxel in patients with non-small-cell lung cancer after disease progression on platinum-based regimen (DUBLIN-3): a phase 3, international, multicentre, single-blind, parallel group, randomised controlled trial

9. ALKTERNATE: A Pilot Study Alternating Lorlatinib With Crizotinib in ALK-Positive NSCLC With Prior ALK Inhibitor Resistance

13. A first-in-class pan-lysyl oxidase inhibitor impairs stromal remodeling and enhances gemcitabine response and survival in pancreatic cancer

14. Influence of environmental changes on power quality disturbances in Hybrid Renewable Energy System

15. Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors

16. Impact of neoadjuvant FOLFIRINOX over upfront resection in borderline resectable pancreatic cancer—an international, multicentre, real-world analysis

18. First-line chemoimmunotherapy and immunotherapy in patients with non-small cell lung cancer and brain metastases: a registry study

20. Five‐year survival and clinical correlates among patients with advanced non‐small cell lung cancer, melanoma and renal cell carcinoma treated with immune check‐point inhibitors in Australian tertiary oncology centres

21. Use of durvalumab in stage III non‐small‐cell lung cancer based on eligibility for the PACIFIC study

24. Design and Construction of a Portable IoT Station

25. Elevated neutrophil‐to‐lymphocyte ratio (NLR) is associated with poorer progression‐free survival in unresectable stage III NSCLC treated with consolidation durvalumab

26. Design and Performance Analysis of a Platform-Based Multi-Phase Interleaved Synchronous Buck Converter.

31. Anti–cytotoxic T-lymphocyte–associated antigen-4 monoclonal antibody quavonlimab in combination with pembrolizumab: Safety and efficacy from a phase I study in previously treated extensive-stage small cell lung cancer

33. Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer

36. Retrospective Evaluation of the Use of Pembrolizumab in Malignant Mesothelioma in a Real-World Australian Population

37. HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer

41. First-line chemoimmunotherapy and immunotherapy in patients with non-small cell lung cancer and brain metastases: A registry study

42. Brief report: Real-world toxicity and survival of combination immunotherapy in pleural mesothelioma—RIOMeso

44. Identification and Characterisation of Infiltrating Immune Cells in Malignant Pleural Mesothelioma Using Spatial Transcriptomics

45. Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer

46. Whole genomes redefine the mutational landscape of pancreatic cancer

47. Author Correction: The landscape of viral associations in human cancers (Nature Genetics, (2020), 52, 3, (320-330), 10.1038/s41588-019-0558-9)

48. Author Correction: The repertoire of mutational signatures in human cancer (Nature, (2020), 578, 7793, (94-101), 10.1038/s41586-020-1943-3)

49. Author Correction: The evolutionary history of 2,658 cancers (Nature, (2020), 578, 7793, (122-128), 10.1038/s41586-019-1907-7)

50. Publisher Correction: Comprehensive molecular characterization of mitochondrial genomes in human cancers (Nature Genetics, (2020), 52, 3, (342-352), 10.1038/s41588-019-0557-x)

Catalog

Books, media, physical & digital resources